Company Overview of Arysta LifeScience Corporation
Arysta LifeScience Corporation develops, markets, and distributes agrochemical solutions. The company offers insecticides, fungicides, herbicides, biostimulants, and value-added nutrients. It offers animal health products for minor species, companion animals, and livestock, including anti-mite treatment for honey bees; cosmetic and pharmaceutical active ingredients and additives, as well as excipients for pharmaceutical and food additive industries; and controlled release fertilizers for the horticulture. The company serves agroscience, and health and nutrition science customers, including wholesalers, retailers, cooperatives, and farmers. It offers its products through sales and marketing r...
St Luke's Tower
Founded in 2001
Key Executives for Arysta LifeScience Corporation
Chief Financial Officer and Representative Director
Chief Operating Officer of Agrochemical Segment
Head of Africa and Western Europe Business Unit
Head of Japan & Central/Eastern Europe Business Unit
Head of Health and Nutrition Science Business Unit
Compensation as of Fiscal Year 2016.
Arysta LifeScience Corporation Key Developments
Arysta Lifescience Corporation Appoints David Jones as a Non- Executive Chairman
Sep 8 15
Arysta Lifescience Corporation appointed David Jones as a Non- Executive Chairman.
Platform To Raise Funds For Arysta
Jan 13 15
Platform Specialty Products Corporation (NYSE:PAH) intends to raise funds to help finance a large portion of its planned $3.5 billion acquisition of Arysta LifeScience Corporation. Platform said that it would offer $500 million of senior notes due 2022 and a 350 million of senior notes, also due 2022, in a private offering, subject to market and other customary conditions.
Platform Specialty Products Reportedly In Advanced Talks To Buy Arysta
Oct 3 14
Platform Specialty Products Corporation (NYSE:PAH) is in advanced talks to acquire Arysta LifeScience Corporation from Permira Advisers Ltd., people familiar with the matter said. A deal that could value Arysta LifeScience Corporation at $3.5 billion, including debt, could come as soon as this month, the people said, cautioning that Permira may decide not to sell the company to Platform Specialty Products and opt to take it public instead. The sources asked not to be identified because the discussions are private. Permira Advisers Ltd. declined to comment, while a representative for Arysta LifeScience Corporation did not immediately respond to a request for comment.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries